fbpx

ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

  • José Baselga, a visionary leader in translational science and precision oncology and VHIO’s Founding Director.

The passing of a visionary in cancer research and clinical oncology: José Baselga, 1959-2021

24/03/2021|Comments Off on The passing of a visionary in cancer research and clinical oncology: José Baselga, 1959-2021

Peptomyc’s Omomyc-based therapy put to the clinical test: first-in-human phase I/II trial approved to assess the efficacy and safety of a novel Myc inhibitor

17/03/2021|Comments Off on Peptomyc’s Omomyc-based therapy put to the clinical test: first-in-human phase I/II trial approved to assess the efficacy and safety of a novel Myc inhibitor

VHIO study reveals Myc-Wnt signaling cross-talk as a culprit of Myc-driven tumorigenesis in pancreatic islets

16/03/2021|Comments Off on VHIO study reveals Myc-Wnt signaling cross-talk as a culprit of Myc-driven tumorigenesis in pancreatic islets

Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO’s Vision 2025

15/03/2021|Comments Off on Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO’s Vision 2025

Spearheading next generation clinical trials: Cancer Core Europe’s design and development of data rich, dynamic studies in oncology

10/03/2021|Comments Off on Spearheading next generation clinical trials: Cancer Core Europe’s design and development of data rich, dynamic studies in oncology

Immune cells in cerebrospinal fluid: predictors of response to immunotherapy against brain metastasis

08/03/2021|Comments Off on Immune cells in cerebrospinal fluid: predictors of response to immunotherapy against brain metastasis

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2019

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER (UITM) – CAIXARESEARCH
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS